



# Precision Medicine Annual Report

## Executive Summary

Precision Medicine identifies disease risk early, often years before symptoms develop, and connects patients to timely care options. Mercy's own Precision Medicine program is one of the nation's most accessible, equitable and comprehensive, bringing life-saving early detection and personalized care to every community we serve.

## Multi-Cancer Early Detection Test

Since 2022, Mercy has partnered with GRAIL to offer our Multi-Cancer Early Detection (MCED) test, which uses a simple blood sample to detect more than 50 types of cancer, including aggressive, often fatal cancers.

Mercy is also currently participating in a three-year research study designed to evaluate the clinical impact of our MCED test among Medicare beneficiaries.

### By the Numbers

**4,712** tests given  
**29** positive cancer signals detected



THE FUTURE OF HEALTH CARE IS HERE

## Germline Testing

Since 2023, Mercy has partnered with Tempus to offer germline testing, which uses a blood test or simple saliva sample to determine a patient's risk for developing certain types of cancer over a lifetime.

### By the Numbers

**6,780** tests given  
**742** pathogenic mutations detected  
**11%** detection rate

## Pharmacogenomics Testing

To better understand how a person may respond to medication, Mercy uses pharmacogenomics testing, which analyzes their genetic data and metabolism to help caregivers prescribe the right medication or dosage for the right person.

Research has shown that treating depression with pharmacogenomics testing can be almost twice as effective as treating without.

In summer 2026, Mercy will add new prescription guidance to EPIC that includes relevant patient pharmacogenomic variants to help providers deliver more timely and clinically effective care.

### By the Numbers

**1,125** patients participated  
**52%** of patients' results supported non-standard medication dosing



## Tempus and OneOme

In February 2026, Mercy began a pharmacogenomic pilot with Tempus and OneOme concerning a class of anti-cancer drugs that are adversely affected by the DPYD gene.

### By the Numbers

**26** reports delivered to date

**3** reports with critical results

## Aidoc

Since 2024, Mercy has partnered with Aidoc to offer 12 FDA-cleared AI algorithms that help providers more accurately diagnose by flagging, triaging and prioritizing suspected findings. In 2026, Mercy will offer four new imaging algorithms, AI for echocardiograms and patient management for coronary artery calcification.

### By the Numbers

Over **2.5 million** imaging studies

**10%** suspected findings

## Tempus Next

Mercy is leveraging Tempus Next to identify breast and lung cancer care gaps. This will help the Precision Medicine team identify patients who may benefit from targeted therapy instead of more conventional chemotherapy and should therefore have biomarker testing completed.

### By the Numbers

**18%** increase in testing rates for all cancer stages

**24%** increase in testing rates for early-stage cancers

**8%** increase in rates for advanced-stage cancers

## Lucem

Lucem Health Reveal is an AI-powered early-disease-detection and clinical-decision platform that helps caregivers identify and manage conditions such as:

- Lung cancer
- Colorectal cancer
- Lower GI disorders
- Liver disease
- Stroke
- Diabetes
- Dysglycemia

Analytics and disease risk insights are derived from patient data to support patient outreach and inform appropriate care recommendations.

To date, Mercy has implemented Lucem products for Type 1 diabetes (T1D) and liver disease. The Precision Medicine, EDAO and Lucem teams are continually refining processes to enable more automated patient outreach and intervention ordering, to scale solutions across Mercy.

## Geneoscopy

Mercy has partnered with Geneoscopy since 2024 to improve access to colorectal cancer screening with ColoSense, an FDA-approved, RNA-based, noninvasive at-home colorectal cancer screening test for average-risk adults aged 45 and older.

### By the Numbers

**98** orders placed

**12** positive screening tests

**3** patients with pre-cancerous polyps removed

## Precision Wellness

Mercy's Precision Wellness program is a complete survey of patients' overall health. Using a combination of screenings, counseling and assessments, Precision Wellness can help detect potential health challenges in patients before they appear.

### Precision Wellness services include:

- Skin exam
- Multi-cancer early detection (MCED) test
- Hereditary cancer screening
- Pharmacogenomic testing
- CT calcium test
- Abdominal aorta ultrasound
- Lipid panel
- A1C blood glucose testing
- Stress management assessment and plan
- Functional fitness assessment
- Nutrition assessment and counseling
- 30-minute massage

Based on the findings in their Precision Wellness visit, patients are given detailed care plans, which may include referrals to cardiologists, dermatologists or oncologists. Mercy's Precision Medicine team has formed direct employer contracts with local organizations interested in providing this service to their executive teams.

## Looking Ahead

Future Precision Medicine programs will expand Mercy's offerings in biomedical technology advancement and genomics. These programs will target:

- Autism and other neurodegenerative disorders
- Adverse drug reactions
- Alzheimer's detection
- Breast cancer (stages 1 and 2)
- Cardiology
- Chronic kidney disease
- Digital pathology
- Ovarian cancer
- Pancreatic cancer
- Polygenic risk scores
- Pulmonary nodules

To learn more about Precision Medicine at Mercy, scan the code or visit [mercy.net/PMsummit](https://mercy.net/PMsummit)



THE FUTURE OF HEALTH CARE IS HERE

